Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.

Item does not contain fulltextGlioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years

The relationship between genetic aberrations as detected by comparative genomic hybridization and vascularization in glioblastoma xenografts.

Item does not contain fulltextAngiogenesis is of vital importance for the growth of solid tumors and constitutes a target for anti-cancer therapy. Glioblastomas (GBMs) are histologically characterized by striking microvascular proliferation. The identification of the mechanism of angiogenesis is of major importance for the further development of anti-angiogenic therapy. Tumor angiogenesis might be the result of a combination of local tissue conditions (especially hypoxia) and specific genetic alterations acquired during oncogenesis. In order to investigate the relationship between genetic aberrations and tumor angiogenesis in GBM xenograft lines, the genetic alterations were examined by Comparative Genomic Hybridization (CGH). Two vascular phenotypes of GBM xenografts could be identified: a well vascularized and a poorly vascularized type. In this model, the poorly vascularized type had a larger number of genetic alterations. However, there was no unequivocal correlation between angiogenesis, growth rate and patterns of genetic alterations as detected by CGH

Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization.

Item does not contain fulltex

Super-resolution reconstruction in MRI:Better images faster?

Improving the resolution in magnetic resonance imaging (MRI) is always done at the expense of either the signal-to-noise ratio (SNR) or the acquisition time. This study investigates whether so-called super-resolution reconstruction (SRR) is an advantageous alternative to direct high-resolution (HR) acquisition in terms of the SNR and acquisition time trade-offs. An experimental framework was designed to accommodate the comparison of SRR images with direct high-resolution acquisitions with respect to these trade-offs. The framework consisted, on one side, of an image acquisition scheme, based on theoretical relations between resolution, SNR, and acquisition time, and, on the other side, of a protocol for reconstructing SRR images from a varying number of acquired low-resolution (LR) images. The quantitative experiments involved a physical phantom containing structures of known dimensions. Images reconstructed by three SRR methods, one based on iterative back-projection and two on regularized least squares, were quantitatively and qualitatively compared with direct HR acquisitions. To visually validate the quantitative evaluations, qualitative experiments were performed, in which images of three different subjects (a phantom, an ex-vivo rat knee, and a post-mortem mouse) were acquired with different MRI scanners. The quantitative results indicate that for long acquisition times, when multiple acquisitions are averaged to improve SNR, SRR can achieve better resolution at better SNR than direct HR acquisitions.</p

Influenza vaccination in children with asthma: randomized double-blind placebo- controlled trial.

There is little evidence that influenza vaccination reduces asthma exacerbations. We determined whether influenza vaccination is more effective than placebo in 6-18-year-old children with asthma. We performed a randomized, double-blind, placebo-controlled trial. Parenteral vaccination with inactivated influenza vaccine or placebo took place approximately November 1, and children were followed until April 1 of the next year. Airway symptoms were reported in a diary. When symptom scores reached a predefined level, a pharyngeal swab was taken. Primary outcome was the number of asthma exacerbations associated with virologically proven influenza infection. Three hundred forty-nine children were assigned placebo, and 347 were assigned vaccine. Pharyngeal swabs positive for influenza were related to 42 asthma exacerbations, 24 in the vaccine group and 18 in the placebo group, a difference of 33% favoring placebo (31% after adjustment for confounders; 95% confidence interval, -34% to 161%). Influenza-related asthma exacerbations were of similar severity in both groups; they lasted 3.1 days shorter in the vaccine group (95% confidence interval, -6.2 to 0.002 days, p = 0.06). We co